Edoxaban-related Spontaneous Renal Hematoma: A Case Report

Edoxaban is an oral anticoagulant drug that directly inhibits factor Xa. It is used for stroke prophylaxis, venous thromboembolism prophy-laxis / treatment, and secondary prophylaxis of acute coronary syndromes. Drug interactions with edoxaban are rare and there is no need for rou-tine blood monitoring. Clinicians should be more aware of potential complications and complica-tion management, as they are prescribed quite frequently. In this article, a spontaneous renal hematoma in a patient using edoxaban for atrial fibrillation-induced stroke prophylaxis is reported. The treatment and follow-up decisions were made by the multidisciplinary team and the patient died despite all efforts. The use of these drugs should be carefully questioned in patients with bleeding who apply to the emergency room because they do not change the coagulation parameters. Larger case series and case reports are needed to develop treatment algorithms for fatal complications that may occur during their use.

Edoxaban Kullanımına Bağlı Spontan Renal Hematom: Olgu Sunumu

Edoxaban faktör Xa’yı doğrudan baskılayan bir oral antikoagülan ilaçtır. Daha az ilaç etkile-şimi ve rutin izleme ihtiyacını ortadan kaldırması nedeniyle; inme profilaksisi, venöz tromboemboli profilaksisi/tedavisi, akut koroner sendromların sekonder profilaksisi için hastalara daha iyi tedavi alternatifleri sağlamıştır. Kullanımı arttıkça klinis-yenlerin potansiyel tedavi riskleri ve komplikas-yon yönetiminden daha fazla haberdar olmaları gerekmektedir. Bu makalede, atriyal fibrilasyon nedenli inme profilaksisi için edoxaban kullanan hastada gelişen spontan renal hematom bildiril-mektedir. Hemodinamik destek sağlanan, görün-tülemeler ile izlenen ve multidisipliner açıdan tedavi ve takip kararları alınan hasta tüm çabala-ra rağmen hayatını kaybetti. Kanama pıhtılaşma değerlerini değiştirmedikleri için acil servise baş-vuran kanamalı hastalarda bu ilaçların kullanım anamnezi dikkatli alınmalıdır. Vakamızda da gös-terildiği gibi kullanımları sırasında gelişebilecek ölümcül komplikasyonlar için tedavi algoritmaları geliştirebilmek için daha geniş vaka serilerine ve olgu sunumlarına ihtiyaç vardır.

Kaynakça

1. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavail-ability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharma-col Drug Dev 2013;2:358-66.

2. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandur-kar H, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleed-ing management. Australasian Society of Thrombosis and Haemostasis. Intern Med J 2014;44:525-36.

3. Schwarb H, Tsakiris DA. New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent J Basel 2016;4:5.

4. Edoxaban versus Warfarin for the Treatment of Symptom-atic Venous Thromboembolism. New England Journal of Medicine 2013;369:1406-15.

5. Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, et al. Mortality in Patients with Atrial Fibril-lation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med 2016;129:850-7-e2.

6. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deena-dayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in pa-tients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.

7. Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016;5.

8. Itagaki H, Katuhiko S. Gallbladder hemorrhage during orally administered edoxaban therapy: a case report. Jour-nal of Medical Case Reports 2019;13:383.

9. Galbiati G. Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edox-aban Therapy: A Case Report. J Blood Med 2020;11:35-8.

10. Tsai TY, Leu HB, Lo LW, Chen SA, Hsu PF. Spontaneous Hemopericardium Complicated with Hemothorax in a Patient Receiving Edoxaban Therapy: A Case Report. Acta Cardiol Sin 2019;35:342-4. 11. Saldanha I, Matos R, Orfao T, Santos M. Tympanic Mem-brane Haematoma in a RivaroxabanTreated Patient: A Case Report. Acta Med Port 2019;32:469-70.

12. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-As-sociated Venous Thromboembolism. New England Journal of Medicine 2017;378:615-24.

13. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gel-bricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-62.

14. Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and Harms of Oral Anticoagulant Ther-apy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019;171:181-9.

15. Scaglione F. New Oral Anticoagulants: Comparative Phar-macology with Vitamin K Antagonists. Clinical Pharmaco-kinetics 2013;52:69-82.

16. Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011;154:311-24.

17. Choudhury M, Chalil S, Abozguia K. Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with edoxaban therapy successfully managed with prothrombin complex concentrate. HeartRhythm Case Rep 2019;6:163-5.

Kaynak Göster

Yeni Üroloji Dergisi
  • ISSN: 1305-2489
  • Yayın Aralığı: Yılda 3 Sayı
  • Başlangıç: 2005

39731

Sayıdaki Diğer Makaleler

Percutaneous Nephrolithotomy is not Frightening in Elderly Patients: A Single Center Outcomes

Yavuz Tarık ATIK, Hacı İ. ÇİMEN, Deniz GÜL, Safa ARSLAN, Fikret HALİS

18 Yaşından Küçük Pediatrik Hastalarda Uygulanan Farklı Perkütan Nefrolitotomi Prosedürlerinin Değerlendirilmesi

Cem ALAN, Onur DEDE

Retrograd İntrarenal Cerrahi Esnasında Oluşan Vücut Sıcaklık Değişikliklerini Etkileyen Faktörler

Vahit GÜZELBURÇ, MuSTAFA SOYTAŞ, Murat Can KİREMİT, Bülent ERKURT, Bülent ALTAY, Kamil DARÇIN, Ziya AKBULUT, Selami ALBAYRAK

Palliative Care Decision in Aging Male With Prostate Cancer

Ersin Erdinç ÇELEBİ, Zülfü SERTKAYA, Musa Ali KUTLUHAN, Selçuk KABA, Metin ÖZTÜRK, Muhammet İhsan KARAMAN

Edoxaban-related Spontaneous Renal Hematoma: A Case Report

yberk İPLİKÇİ, Özgür EFİLOĞLU, Asıf YILDIRIM

The Effectiveness of Topical Steroid Cream in the Management of Phimosis Developed Following Circumcision Performed With Thermocautery

Osman AKYÜZ, Mehmet Nuri BODAKÇI, Zeynep TATAR, Müslüm ERGÜN, Soner ÇOBAN, Haydar Kamil ÇAM

Prostatın Pür Leiomyomu: Olgu Sunumu

Jamal MUYASEV, Asif JAHANGİROV, Adalat HASANOV, Mahmud BAGHİRZADE

Role of Prostate Specific Antijen in Prostatic Adenocarcinoma Detection in Patients With Benign Prostate Hyperplasia and Were Placed Urethral Catheter After Acute Urinary Retention

Ahmet HACIİSLAMOĞLU, İsmail EVREN, Abdullah Hızır YAVUZSAN, İsmail YİĞİTBAŞI, Mithat EKŞİ, Kamil Gökhan ŞEKER, Volkan TUĞCU

Current Diagnosis, Treatment And Follow-up Procedures of Paratesticular Masses

Mustafa Gürkan YENİCE, Ramazan UĞUR, İsmail YİĞİTBAŞI, Kamil Gökhan ŞEKER, Halil BAYTEKİN, Yavuz Onur DANACIOĞLU, Selçuk ŞAHİN, Ali İhsan TAŞÇI

İleri Yaş Kas İnvaziv Olmayan Mesane Kanserli Hastalarda Rekürens ve Progresyon Gelişimine Etkilidir

Göksel BAYAR, Muhammet Fatih KILINÇ